Drug
Anakinra Prefilled Syringe
Anakinra Prefilled Syringe is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Terminated(1)
Other(2)
Detailed Status
unknown2
Terminated1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
unknown250%
terminated125%
completed125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes
NCT04227769
completedphase_2
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia
NCT05785442
unknownphase_2
A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
NCT04412291
unknownphase_2
IL-1ra Dose-range Study for Moderate-to-severe TBI Patients
NCT02997371
Clinical Trials (4)
Showing 4 of 4 trials
NCT04227769Phase 2
IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes
NCT05785442Phase 2
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia
NCT04412291Phase 2
A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
NCT02997371Phase 2
IL-1ra Dose-range Study for Moderate-to-severe TBI Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4